somapacitan-beco
| Brand name | Sogroya |
|---|---|
| Active ingredient | somapacitan-beco |
| Strength | 5MG/1.5ML (3.3MG/ML) |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | October 2021 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.